Nieto-Martínez Ramfis, González-Rivas Juan P, Ugel Eunice, Marulanda Maria Ines, Durán Maritza, Mechanick Jeffrey I, Aschner Pablo
South Florida Veterans Affairs Foundation for Research & Education and Geriatric Research, Education and Clinical Center (GRECC), Miami VA Healthcare System, Miami, FL, USA; Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Physiology, School of Medicine, University Centro-Occidental "Lisandro Alvarado" and Cardio-Metabolic Unit 7, Barquisimeto, Venezuela; Foundation for Clinical, Public Health, and Epidemiological Research of Venezuela (FISPEVEN), Caracas, Venezuela.
Foundation for Clinical, Public Health, and Epidemiological Research of Venezuela (FISPEVEN), Caracas, Venezuela; The Andes Clinic of Cardio-Metabolic Studies, Mérida, Venezuela.
Prim Care Diabetes. 2019 Dec;13(6):574-582. doi: 10.1016/j.pcd.2019.04.006. Epub 2019 Jun 13.
To evaluate the performance of the Latin American Finnish Diabetes Risk Score (LA-FINDRISC) compared with the original O-FINDRISC in general population. To establish the best cut-off to detect unknown type 2 diabetes (uT2D) and prediabetes.
The EVESCAM was a national population-based, cross-sectional, randomized cluster sampling study, which assessed 3454 adults from July 2014 to January 2017. Those with self-report of diabetes were excluded; a total of 3061 subjects were analyzed. Waist circumference adapted for Latin America was the difference between the LA-FINDRISC and the O-FINDRISC. The area under the curve (AUC), sensitivity, and specificity were calculated.
The prevalence of uT2D and prediabetes were 3.3% and 38.5%. The AUC with the LA-FINDRISC vs. the O-FINDRISC were: for uT2D, 0.722 vs. 0.729 in men (p=0.854) and 0.724 vs. 0.732 in women (p=0.896); for prediabetes (impaired fasting glucose [IFG] + impaired glucose tolerance [IGT], 0.590 vs. 0.587 in men (p=0.887) and 0.621 vs. 0.627 in women (p=0.777); for IFG, 0.582 vs. 0.580 in men (p=0.924) and 0.607 vs. 0.617 in women (p=0.690); for IGT, 0.691 vs. 0.692 in men (p=0.971) and 0.672 vs. 0.671 in women (p=0.974). Using the LA-FINDRISC, the best cut-offs to detect uT2D were 9 in men and 10 in women and to detect IGT was 9 in both genders.
LA-FINDRISC has similar performance than O-FINDRISC in Venezuelan adults and showed a good performance to detect uT2D and IGT, but not IFG. The best cut-offs to detect glucose alterations were established.
评估拉丁美洲芬兰糖尿病风险评分(LA - FINDRISC)与原始的O - FINDRISC在一般人群中的表现。确定检测未知2型糖尿病(uT2D)和糖尿病前期的最佳临界值。
EVESCAM是一项基于全国人群的横断面随机整群抽样研究,于2014年7月至2017年1月对3454名成年人进行了评估。排除那些自我报告患有糖尿病的人;共分析了3061名受试者。适合拉丁美洲的腰围是LA - FINDRISC与O - FINDRISC之间的差异。计算曲线下面积(AUC)、敏感性和特异性。
uT2D和糖尿病前期的患病率分别为3.3%和38.5%。LA - FINDRISC与O - FINDRISC的AUC分别为:对于uT2D,男性为0.722对0.729(p = 0.854),女性为0.724对0.732(p = 0.896);对于糖尿病前期(空腹血糖受损[IFG] +糖耐量受损[IGT]),男性为0.590对0.587(p = 0.887),女性为0.621对0.627(p = 0.777);对于IFG,男性为0.582对0.580(p = 0.924),女性为0.607对0.617(p = 0.690);对于IGT,男性为0.691对0.692(p = 0.971),女性为0.672对0.671(p = 0.974)。使用LA - FINDRISC,检测uT2D的最佳临界值男性为9分,女性为10分,检测IGT的最佳临界值男女均为9分。
LA - FINDRISC在委内瑞拉成年人中的表现与O - FINDRISC相似,在检测uT2D和IGT方面表现良好,但在检测IFG方面表现不佳。确定了检测血糖改变的最佳临界值。